Inability of cells to detoxify reactive oxidative species (ROS) is responsible for numerous degenerative pathological conditions. Currently there is no clinical method to assess reduction-oxidation (redox) state in vivo. In this study, using a cyclic nitroxide T1 MR probe with unique characteristics, we propose a two-tissue compartment model which provides quantitative information of markers of oxidative stress. Results demonstrated the feasibility of redox status assessment in vitro and in vivo in the stenotic mouse kidney. In the stenotic kidney, our method indicated increased renal ROS production, accompanied by preserved ability to detoxify ROS compared to the contralateral kidney.
Unperturbed biological systems have the ability to detoxify reactive oxygen species (ROS) and maintain a delicate reduction-oxidation (redox) balance. Cellular injury may disturb this balance and result in increased oxidative stress, which exerts deleterious effects on proteins, lipids, and DNA, and is responsible for numerous degenerative neurological, cardiovascular, renal, and other pathologies1-3. Currently methods for assessing oxidative stress in vivo are unsuitable for clinical translation, mainly due to their invasive nature (biopsy) or lack of clinical availability (EPR spectroscopy). In this study, we introduce a novel analysis method for quantitative MRI-based assessment of markers of oxidative stress using Tempol, a T1 MR tracer (Figure 1) and superoxide dismutase (SOD) mimetic. The absence of advanced knowledge describing the pharmacokinetics of Tempol within the tissue makes it difficult to discern dynamics of T1 contrast secondary to its reduction or re-oxidization following inflow and clearance from the organ of interest. To alleviate this limitation, we propose a novel kinetic model that accounts for the uptake and washout of Tempol, and deconvolves quantitative markers of ROS generation and cellular detoxification capability from the kinetic information.
1. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current neuropharmacology. 2009;7(1):65-74.
2. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003 Oct 21;108(16):1912-6.
3. Stanton RC. Oxidative stress and diabetic kidney disease. Current diabetes reports. 2011;11(4):330-6.
4. Ebrahimi B, Crane JA, Knudsen BE, Macura SI, Grande JP, Lerman LO. Evolution of cardiac and renal impairment detected by high-field cardiovascular magnetic resonance in mice with renal artery stenosis. Journal of Cardiovascular Magnetic Resonance. 2013;15(1):1.
5. Metropolis N, Ulam S. The monte carlo method. Journal of the American statistical association. 1949;44(247):335-41.
6. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E. Equation of state calculations by fast computing machines. The journal of chemical physics. 1953;21(6):1087-92.
7. Sitek A, Li Q, El Fakhri G, Alpert NM. Validation of Bayesian analysis of compartmental kinetic models in medical imaging. Physica Medica. 2016;32(10):1252-8.
8. Chang JM, Kuo MC, Kuo HT, Chiu YW, Chen HC. Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. Journal of Laboratory and Clinical Medicine. 2005;146(4):210-5.
9. Wilcox CS, Pearlman A. Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacological reviews. 2008;60(4):418-69.
10. Spinale FG, Mukherjee R, Fulbright BM, Hu J, Crawford FA, Zile MR. Contractile properties of isolated porcine ventricular myocytes. Cardiovascular research. 1993;27(2):304-11.
Table 1. Indices of RAS development in mice. Three weeks after RAS, animals tended to be hypertensive (p=0.06); (* p<0.05 vs. CLK).